General Information of Drug (ID: DM389YD)

Drug Name
Diazepinone derivative 4 Drug Info
Synonyms PMID28067079-Compound-87
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Patented [1]
Reflux disease DA22 Patented [1]
Cross-matching ID
PubChem CID
73335441
TTD Drug ID
DM389YD

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AFQ056 DMMHSLC Fragile X syndrome LD55 Phase 2/3 [2]
ADX-48621 DM6GTMD Parkinson disease 8A00.0 Phase 2/3 [3]
RG-7090 DMX8JYN Fragile X syndrome LD55 Phase 2 [4]
STX-107 DMLNKX7 Autism spectrum disorder 6A02 Phase 2 [5]
ADX10059 DMGVKHQ Anxiety disorder 6B00-6B0Z Phase 2 [6]
McN3377 DMTCADJ Fragile X syndrome LD55 Phase 1/2 [7]
MK-3328 DMW2O5D Alzheimer disease 8A20 Phase 1 [8]
[3H]fenobam DMBOXA1 Allodynia MB40.1 Phase 1 [9]
RG7342 DMIW5NG Schizophrenia 6A20 Phase 1 [10]
BMS-984923 DMFNDUL Alzheimer disease 8A20 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Metabotropic glutamate receptor 5 (mGluR5) TTHS256 GRM5_HUMAN Modulator [1]

References

1 mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
2 Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos. 2013 Sep;41(9):1626-41.
3 Pipeline of Addex Pharma. Addex Pharma. 2009.
4 The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231(6): 1237-1250.
5 Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30.
6 A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and... Gut. 2009 Sep;58(9):1192-9.
7 Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
9 Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agon... J Pharmacol Exp Ther. 2005 Nov;315(2):711-21.
10 Clinical pipeline report, company report or official report of Roche.
11 Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes. Cell Rep. 2017 Jul 5;20(1):76-88.